Do All Hepatitis B Patients Need Antiviral Medicine? How Specialists Decide

The result arrives on a Tuesday, buried in a routine panel ordered for a new job, a pregnancy or a blood donation: hepatitis B surface antigen, positive. The person reading it feels perfectly well. No yellow eyes, no pain, nothing. Then the question that follows almost everyone into the specialist’s office comes out in a rush: do I need treatment for hepatitis B, and if not now, when?

It is a fair question, and the honest answer is more layered than a yes or a no. Hepatitis B is one of the few chronic viral infections where doctors routinely, and deliberately, choose not to prescribe medicine for some people while starting it promptly for others. That is not indecision. It reflects how the virus behaves, how the immune system responds to it, and what the medicines can and cannot do.

This explainer walks through the reasoning specialists use, test by test and phase by phase, so the conversation in that office feels less like a verdict and more like a plan you understand.

Do I need treatment for hepatitis B? The honest short answer

Some people do, many do not, and almost everyone needs follow-up. That sentence frustrates people who want a clean answer, yet it is the most accurate summary of every major guideline.

The World Health Organization estimates that about 254 million people were living with chronic hepatitis B infection in 2022, and that only a small fraction were receiving antiviral therapy (WHO). Part of that gap is a genuine failure of access and diagnosis. Part of it, however, is by design: guidelines have historically reserved medicine for people whose livers show evidence of active harm, because the drugs suppress the virus rather than remove it, and once started they are often continued for years.

The decision therefore turns on a handful of questions. Is the infection acute or chronic? How much virus is circulating? Is the liver inflamed right now, as shown by enzyme levels? Has scarring already begun? Are there other conditions, such as HIV, pregnancy, or a planned course of chemotherapy, that change the calculation? Is there a family history of liver cancer?

No single test settles it. A specialist reads several results together, often repeated over months, and places the person in a recognizable pattern. Someone with cirrhosis, the advanced scarring stage, is generally treated regardless of other numbers (WHO). Someone with very little virus, normal enzymes and a healthy-looking liver is generally monitored instead.

Between those two poles sits a large middle group, and it is here that clinical judgment, patient preference and evolving evidence all matter. Recent WHO guidance has broadened the pool of people considered eligible for treatment, which means the answer a person received a decade ago may not be the answer today. The treating team makes the call, ideally with the patient understanding exactly why.

Can hepatitis B go away naturally? Acute versus chronic infection

Age at infection decides almost everything here. Fewer than 5% of otherwise healthy adults who catch hepatitis B go on to develop chronic infection; their immune system clears the virus over weeks to months (WHO). By contrast, 80–90% of infants infected in the first year of life and 30–50% of children infected before age six develop lifelong infection (WHO). A newborn’s immune system, still learning what to attack, tends to tolerate the virus rather than fight it.

Doctors define the boundary at six months. If the surface antigen, a protein on the virus’s outer coat, is still detectable in the blood after six months, the infection is called chronic (NHS; CDC). Before that mark, it is acute, and for most adults the treatment is supportive: rest, fluids, avoiding alcohol and unnecessary medicines that stress the liver, and repeat blood tests to confirm clearance (Mayo Clinic). Antiviral medicine is rarely used in the acute phase, reserved for the uncommon person whose liver is failing.

Most people never notice an acute infection at all. WHO notes that the majority have no symptoms when first infected, which is exactly why so many chronic infections are discovered by accident years later, often long after a childhood exposure nobody remembers.

Once chronic, the virus rarely disappears completely. It deposits a stable circular form of its genetic material, called cccDNA, inside the nucleus of liver cells, where current medicines cannot reach it. A small minority of people do lose the surface antigen spontaneously over the years, a state doctors sometimes call functional control, but this is the exception. For everyone else, “gone” is not the realistic goal; “controlled” is.

What hepatitis B actually does inside the liver

The virus itself is a surprisingly quiet tenant. It moves into liver cells, called hepatocytes, and uses their machinery to make copies of itself without directly killing them. The damage comes from the landlord, not the tenant: the immune system recognizes infected cells and attacks them.

That attack is inflammation. When liver cells are injured, they leak an enzyme called alanine aminotransferase, or ALT, into the blood, which is why ALT is the single most watched number in hepatitis B care. A rising ALT means the immune system is actively fighting, and liver cells are dying in the crossfire.

Repeated cycles of injury and repair leave scar tissue. Early scarring is called fibrosis; when it becomes extensive enough to distort the liver’s structure and impair its function, it is called cirrhosis. A cirrhotic liver may still work for years, but it loses its reserve, and it becomes the soil in which liver cancer most often grows.

Hepatitis B carries an additional hazard. Because pieces of viral DNA can integrate into the DNA of liver cells, hepatocellular carcinoma, the main form of primary liver cancer, can arise even before cirrhosis develops. This is one reason specialists sometimes recommend treatment or surveillance for people whose livers look healthy on the surface.

The stakes explain the caution. WHO estimated that hepatitis B caused about 1.1 million deaths in 2022, mostly from cirrhosis and hepatocellular carcinoma (WHO). WHO has also estimated that roughly 20–30% of adults with chronic infection eventually develop cirrhosis, liver cancer, or both if the disease is not managed (WHO). Treatment decisions are ultimately about interrupting that long, silent sequence before it reaches its final chapters.

The blood tests and scans specialists read before deciding

A hepatitis B workup is a set of markers that, read together, tell a story about where the virus and the immune system stand.

The surface antigen (HBsAg) confirms infection. Its antibody (anti-HBs) indicates immunity, either from vaccination or recovery. Core antibody (anti-HBc) shows past or present exposure and helps distinguish a vaccinated person from someone who once had the virus (CDC).

The e antigen (HBeAg) is a protein the virus releases while replicating vigorously. Its presence usually means high viral activity; when the body produces antibody against it (anti-HBe), replication often slows. Specialists watch for this switch because it frequently marks a shift into a quieter phase.

HBV DNA, commonly called viral load, measures how many copies of viral genetic material are circulating. It is the direct readout of how busy the virus is. Alongside it, ALT reflects how hard the immune system is pushing back.

Liver structure is assessed separately. Ultrasound looks for surface irregularity, spleen enlargement and masses. Transient elastography, a painless scan that measures liver stiffness with a gentle pulse, estimates fibrosis without a needle. Platelet counts and albumin levels hint at how well the liver is functioning. A biopsy is now reserved for cases where the picture stays unclear (Mayo Clinic).

Two further tests shape the decision even though they are not about the liver directly: HIV, hepatitis C and hepatitis D status, because coinfection changes both risk and treatment; and, for people who may become pregnant, pregnancy status, since viral load in late pregnancy affects the baby’s risk.

Because many of these values fluctuate, one snapshot is rarely enough. Specialists typically repeat ALT and viral load over several months before labeling a phase, unless scarring or symptoms make waiting unwise.

The phases of chronic hepatitis B, and why 'inactive' is not 'gone'

Chronic hepatitis B is not one condition but a moving picture, and guidelines describe it in phases. Knowing which phase you are in explains most of what your specialist decides.

The first phase, sometimes called immune-tolerant or HBeAg-positive chronic infection, is common in people infected at birth. Viral load is very high, yet ALT is normal because the immune system is largely ignoring the virus. The liver often shows little damage. Historically, most guidelines advised monitoring rather than treatment here, though newer WHO guidance takes a more permissive view for some adults.

The second phase is immune-active, or HBeAg-positive chronic hepatitis. The immune system wakes up, ALT rises, and liver cells are damaged. This is a phase where treatment is often recommended.

Many people then convert to anti-HBe and enter an inactive phase, HBeAg-negative chronic infection, with low viral load and normal ALT. The liver rests. People in this phase generally do well and are monitored rather than treated.

Some, however, move into HBeAg-negative chronic hepatitis, where a mutated virus replicates despite the antibody. Viral load and ALT fluctuate, sometimes normal at one visit and clearly abnormal at the next. This phase is easy to misread as inactive if tests are done only once, and it carries a real risk of progressive scarring.

A final phase, resolved or HBsAg-negative infection, means the surface antigen has been lost. Even then, cccDNA persists in liver cells, and the virus can reactivate if the immune system is heavily suppressed.

People do not march through these phases in order, and they can move backward. That is the practical reason “inactive” never means discharged from care.

Who is usually offered antiviral medicine, and who is usually asked to wait

Guidelines from WHO, national health services and liver societies differ in details, but they converge on the same broad groups.

Treatment is generally recommended for anyone with cirrhosis, whether it was found on a scan, a biopsy, or a stiffness measurement, and regardless of how low the viral load appears (WHO). Scar tissue already present means the liver has little margin left.

It is also recommended for people with active hepatitis: a raised ALT combined with a meaningful viral load, particularly when significant fibrosis is present. The exact thresholds vary between guidelines and have been lowered over time, which is why the same numbers can produce different advice in different years or countries.

Several situations tip the balance toward treatment independent of liver findings. These include coinfection with HIV, hepatitis C or hepatitis D; a first-degree relative with liver cancer; a planned course of chemotherapy or strong immunosuppression, where reactivation can be dangerous; late pregnancy with a high viral load, to lower the chance of passing the virus to the baby; and complications outside the liver, such as certain kidney or blood-vessel inflammations linked to the virus (WHO; Mayo Clinic).

Who is asked to wait? Typically people in the inactive phase with low viral load, normal ALT and no fibrosis, and, in many but not all guidelines, younger adults in the immune-tolerant phase with normal ALT and a healthy-appearing liver. “Wait” is the wrong word, really. These people are placed under scheduled surveillance so that a change in phase is caught early.

Patient preference matters too. Someone anxious about cancer risk, or someone who struggles to attend frequent monitoring, may reasonably discuss earlier treatment with their team. The team weighs benefit against years of daily medicine and decides together with the patient.

Treat now or monitor: how the main scenarios compare

The table below summarizes patterns specialists recognize. It is a map, not a rulebook; individual results, other illnesses and the guideline your team follows can shift any row.

Situation	What tests usually show	Typical guideline approach
Acute infection in a healthy adult	New HBsAg, raised ALT, sometimes jaundice	Supportive care; repeat testing to confirm clearance; antivirals only if liver failure threatens
Inactive chronic infection	HBeAg-negative, low viral load, normal ALT, no fibrosis	Regular monitoring, no medicine
Immune-active chronic hepatitis	High viral load, raised ALT, with or without fibrosis	Treatment usually recommended
Compensated or decompensated cirrhosis	Scarring on scan or biopsy, any viral load	Treatment recommended plus cancer surveillance
Immune-tolerant young adult	Very high viral load, normal ALT, healthy liver	Monitoring in many guidelines; treatment considered in newer WHO guidance
Pregnancy with high viral load	High HBV DNA in later pregnancy	Antiviral often offered in third trimester to protect the baby, plus newborn vaccination
Planned chemotherapy or immunosuppression	Any phase, including resolved infection	Preventive antiviral commonly recommended to avoid reactivation

Two points deserve emphasis. First, cirrhosis overrides everything else; a low viral load does not make a scarred liver safe. Second, the middle rows are where evidence is still evolving. Studies have shown liver cancer arising in people once considered low risk, which is why WHO’s most recent guidance widened eligibility and simplified criteria so that more adults can be treated in settings without advanced testing (WHO).

If your results place you in a monitoring row, the sensible question is not “why am I not being treated?” but “what change in my numbers would move me to a treatment row, and how often will we check?”

How hepatitis B antivirals work, and what they cannot do

Two classes of medicine exist. Neither is a recommendation here; the choice belongs to the prescribing clinician.

The mainstay is a class called nucleoside or nucleotide analogues, oral medicines that mimic the building blocks the virus uses to copy its genetic code. When the viral enzyme picks up the impostor, copying stalls. Generic names in this class include entecavir and tenofovir (Mayo Clinic). Because they act on replication rather than on the immune system, they lower viral load steadily and reliably, and modern agents rarely lose effectiveness through resistance.

The limitation is fundamental. These medicines do not remove cccDNA, the viral template lodged in liver cell nuclei. Stop the medicine and the template resumes production. For that reason, treatment is often continued for many years, and for people with cirrhosis it is generally indefinite (Mayo Clinic). Stopping without supervision can trigger a sharp rebound of virus and inflammation, occasionally severe, so any change is a decision for the prescribing team, never a solo one.

The second class is pegylated interferon, an injectable form of a natural immune-signaling protein. It aims to help the immune system control the virus and is given as a time-limited course rather than open-ended. It carries more side effects, including fatigue, mood changes and blood count changes, and suits a smaller group of people (Mayo Clinic).

What treatment achieves is well documented: suppressed viral load, normalized ALT, less inflammation, and over time, partial reversal of fibrosis in many people, with a lower risk of progression to cirrhosis and liver cancer. What it does not do is eliminate the infection or remove the need for cancer surveillance in people who already had cirrhosis. Expectations set correctly at the start make the long road easier.

Can I live with hepatitis B without treatment? What monitoring really involves

Yes, many people do, for decades, and do so healthily. The condition is that “without treatment” never means “without care.”

Monitoring is structured. WHO guidance advises that everyone diagnosed with chronic hepatitis B who does not start medicine should have regular reassessment, at least yearly, of ALT, viral load and liver status, with closer intervals when results are borderline or shifting (WHO). Your team sets the schedule; the point is to catch the move from an inactive phase to an active one before scarring accumulates.

People at higher risk of liver cancer, including those with cirrhosis, a family history of the disease, or older age, are usually offered periodic ultrasound surveillance, sometimes with a blood marker called alpha-fetoprotein. Small tumors found this way are far more treatable than those found once symptoms appear.

Daily life carries a few evidence-based adjustments. Alcohol multiplies liver injury and is best avoided or kept minimal (NHS). Fatty liver from excess weight or diabetes adds a second driver of scarring, so metabolic health directly protects the liver. Some herbal and bodybuilding supplements have caused liver damage; tell your team about anything you take. Vaccination against hepatitis A is commonly recommended, since a second viral hepatitis on top of the first is harder on the organ.

Protecting others is part of the plan. Hepatitis B spreads through blood, semen and vaginal fluids, not through food, water, hugging, coughing or sharing utensils (CDC). Household and sexual contacts should be tested and vaccinated if not immune; razors and toothbrushes should not be shared; condoms protect partners who are not yet immune.

Living well with untreated hepatitis B is entirely realistic. It simply asks for a relationship with a care team that continues across years, not a one-time visit.

The first weeks and months after starting hepatitis B treatment

For people who do start an oral antiviral, the early experience is usually undramatic, which surprises those braced for something harsher.

The medicine is taken at home, long term, with the schedule set by the prescriber. Most people notice few or no side effects; when they occur, they tend to be mild, such as nausea, headache or tiredness in the first weeks (Mayo Clinic). Certain agents in the class can affect kidney function or bone density over years, so baseline and periodic checks of kidney markers are routine, and the choice of agent takes existing kidney disease into account.

The virus responds first. Viral load typically falls over the first months and, for most people on modern agents, eventually becomes undetectable on standard tests (Mayo Clinic). ALT follows more slowly, because inflammation settles after replication stops, not before. Improvement in liver stiffness, if it comes, is measured in years.

Follow-up blood tests in the first year are relatively frequent, then space out once suppression is stable. If you have cirrhosis, cancer surveillance continues in parallel, because suppressing the virus lowers but does not erase the risk that prior scarring created.

Adherence is the quiet determinant of success. Missed medicine allows viral rebound, and a pattern of missed doses raises the small risk of resistance. Practical tools, such as a fixed daily routine, phone reminders or linking the medicine to another habit, help more than willpower. If side effects, cost concerns or life circumstances make continuing hard, that is a conversation to have promptly with the team rather than a reason to stop quietly.

Emotionally, the first months often bring relief. Numbers move in the right direction, and a diagnosis that felt like a threat becomes a managed condition with a plan.

Special situations that change the decision: pregnancy, immunosuppression and coinfection

Some circumstances push the treatment question in a different direction, not because the liver is worse but because someone else, or a future version of the patient, is at risk.

Pregnancy is the clearest example. The CDC recommends testing every pregnant person for hepatitis B in every pregnancy (CDC). If the mother has a high viral load in the third trimester, guidelines commonly recommend an antiviral for the final weeks to reduce the amount of virus the baby is exposed to at birth. Whether or not the mother takes medicine, the newborn should receive the first vaccine dose and hepatitis B immune globulin, a preparation of ready-made antibodies, within 12 hours of birth (CDC), followed by the remaining vaccine series. Together these measures prevent the great majority of mother-to-child transmissions. Breastfeeding is considered safe once the infant has received these protections (CDC).

Planned immunosuppression is the second. Chemotherapy, certain biologic drugs for rheumatoid arthritis or inflammatory bowel disease, high-dose steroids and transplant medicines can release the brakes on a dormant virus, and reactivation can be severe. This applies even to people whose infection resolved years earlier, because cccDNA persists. Guidelines recommend testing before such therapy begins and often a preventive antiviral throughout, decided jointly by the liver specialist and the treating oncologist or rheumatologist.

Coinfection is the third. HIV shares the same routes of transmission and speeds liver damage; treatment plans must cover both viruses in a coordinated way. Hepatitis D, a virus that can only infect people who already have hepatitis B, causes faster progression and calls for specialist input. Hepatitis C coinfection requires careful sequencing, since treating one virus can unmask the other.

Children with chronic infection are usually monitored, with treatment considered when inflammation is active; pathways, comfort and family testing matter more than medicine in most cases.

Can I still get hepatitis B if I was vaccinated? Protection, gaps and testing

The hepatitis B vaccine is one of the most effective in medicine. WHO reports it to be 98–100% protective when the full series is completed, with protection lasting at least 20 years and probably for life (WHO). So the short answer is that a fully vaccinated person who responded to the vaccine is very unlikely to become infected.

Three gaps explain the exceptions. First, some people do not mount a protective antibody response. Older age, obesity, smoking, kidney dialysis, HIV and other immune-weakening conditions make this more likely (CDC). Health workers, dialysis patients and partners of infected people are often tested for anti-HBs after vaccination for exactly this reason; a non-responder may be offered a repeat series.

Second, the series may have been incomplete or given long before records were kept, leaving a person uncertain of their status. Third, and most important, vaccination cannot treat or remove an infection that was already present. Someone infected at birth who was later vaccinated as a child still carries the virus; the vaccine simply had nothing to prevent.

This last point matters because routine infant vaccination arrived at different times in different countries. Adults born before those programs, or in regions where the virus is common, may have lived for decades unaware. The CDC now recommends that all adults be screened for hepatitis B at least once, using a panel that includes HBsAg, anti-HBs and anti-HBc (CDC).

Reading the panel is straightforward. Anti-HBs alone means vaccine immunity. Anti-HBs with anti-HBc means past infection that resolved. HBsAg present means current infection, and the question of treatment begins. A single set of three tests sorts most people into the right path.

What people often get wrong about hepatitis B and its treatment

Myths around this virus cause real harm, either by frightening people who are doing well or by reassuring people who are not.

Feeling fine means the liver is fine. Not necessarily. The liver has no pain nerves in its tissue and enormous reserve; cirrhosis can develop without a single symptom. Blood tests and scans, not sensations, measure the disease.

A normal ALT means no treatment is ever needed. A single normal ALT is reassuring but not conclusive, especially in HBeAg-negative disease where values fluctuate. Repeated testing over time is what specialists trust.

Being a “carrier” means you cannot pass it on. People with low viral load are less infectious but not non-infectious. Contacts should be tested and vaccinated (CDC).

It spreads through food, water or casual contact. It does not. Transmission requires blood, semen or vaginal fluid, or birth from an infected mother (CDC; MedlinePlus). Sharing a meal, a hug or a bathroom is safe.

Treatment is a short course that ends the infection. Oral antivirals suppress rather than eliminate the virus and are usually long term (Mayo Clinic). Anyone promising a quick, permanent fix is not describing current medicine.

Herbal or traditional remedies can clear the virus. No herbal product has been shown in rigorous trials to suppress hepatitis B, and several have caused serious liver injury. Tell your team about any supplement before taking it.

Once treated, the risk is gone. Suppression greatly lowers risk of progression, but people who already had cirrhosis remain under cancer surveillance.

Hepatitis B means liver cancer is inevitable. It does not. Most people with chronic infection never develop cancer, particularly with monitoring, alcohol avoidance and treatment when indicated. The diagnosis is a reason for vigilance, not despair.

Questions to ask your care team about whether you need hepatitis B treatment

Consultations run short, and the questions that matter tend to arrive in the parking lot afterward. Bringing a written list changes that. These are the ones that shape the treatment decision most directly.

• Is my infection acute or chronic, and how do you know?
• Which phase of chronic hepatitis B do my results suggest, and how confident are you given a single set of tests?
• What are my current viral load and ALT, and what changes in those numbers would move me toward treatment?
• Is there any evidence of fibrosis or cirrhosis on my scan or stiffness measurement? What stage?
• Have I been tested for HIV, hepatitis C and hepatitis D?
• Do I need surveillance for liver cancer, and if so, how often and with what test?
• How often will you recheck my blood tests, and who contacts whom if a result changes?
• If treatment is recommended, which class of medicine are you considering, why that one, and how long do you anticipate it would continue?
• What side effects should I watch for, and which of my other medicines or health conditions affect the choice?
• What would happen if I stopped the medicine, and how would we plan any future change together?
• Are there guidelines you follow, and has your recommendation for someone like me changed in recent years?
• Who in my household should be tested or vaccinated, and how do I arrange that?
• Is there anything about my diet, alcohol, supplements or weight that you would prioritize?
• If I plan a pregnancy or am prescribed chemotherapy or immunosuppressants in future, how should I flag it?

The answers will not all come at once, and some will be “we need another set of results to say.” That is a legitimate answer. The goal is to leave understanding the logic of your own plan, so that a recommendation to wait feels like surveillance rather than neglect, and a recommendation to treat feels like a decision you helped make.

When to call your doctor

Most people with hepatitis B will go years between appointments without a single alarming moment. A short list of red flags is still worth knowing, because the liver tends to stay silent until it cannot.

Seek urgent medical care, the same day or through emergency services, if you notice yellowing of the skin or the whites of the eyes, dark tea-colored urine or pale clay-colored stools, which signal that bilirubin is building up; new confusion, drowsiness or personality change, which can indicate that toxins the liver normally clears are affecting the brain; vomiting blood or passing black, tarry stools, which may mean bleeding from enlarged veins; rapid swelling of the abdomen or legs; severe pain under the right ribs; or unusual bruising and bleeding (NHS; MedlinePlus).

Call your care team promptly, though not necessarily as an emergency, if you develop persistent fatigue, nausea or loss of appetite that lasts more than a few days; if you have missed your antiviral medicine for more than a few days or have stopped it for any reason; if another doctor prescribes chemotherapy, a biologic, high-dose steroids or any new long-term medicine; if you become pregnant or are planning to; if a household member or partner tests positive; or if a scheduled monitoring visit has been missed and you are unsure of your next step.

People who have stopped antiviral therapy, whether by decision or by lapse, deserve particular vigilance in the months that follow, because flares can occur once the virus rebounds. Report any of the symptoms above without waiting for the next routine appointment.

None of these signs is a diagnosis on its own. They are reasons for a clinician to look, quickly. Your treating team is the right place for every decision that follows, from repeating a test to starting or adjusting medicine.

Frequently asked questions

Do I need to worry if I have hepatitis B?

A diagnosis calls for attention, not panic. Most people with chronic hepatitis B who are monitored regularly, avoid alcohol and start treatment when their team advises never develop cirrhosis or liver cancer. The risk is real but manageable, and it is highest in people who go undiagnosed or unmonitored for decades. Your first steps are a full set of blood tests and a liver scan so a specialist can tell you which phase you are in.

Can I live with hepatitis B without treatment?

Yes, many people do for decades. Those in the inactive phase, with low viral load, normal liver enzymes and no scarring, are usually monitored rather than treated. Living without treatment does require regular follow-up, at least yearly according to WHO guidance, because the infection can shift into an active phase without symptoms. Alcohol avoidance, metabolic health and cancer surveillance for higher-risk people complete the plan.

Can hepatitis B go away naturally?

In adults with a new infection, usually yes: fewer than 5% develop chronic infection, according to WHO, and the rest clear the virus within months. Once infection has been present for more than six months, spontaneous loss of the surface antigen does happen but only in a small minority of people over many years. For most people with chronic infection, the realistic goal is control through monitoring or medicine rather than disappearance.

Can I still get hepatitis B after vaccination?

It is unlikely if you completed the series and responded to it. WHO reports the vaccine is 98–100% protective, with immunity lasting at least 20 years and probably for life. Some people, especially older adults, smokers, those with obesity, kidney dialysis or weakened immunity, do not respond fully and may be tested and revaccinated. The vaccine also cannot clear an infection acquired before it was given, which is why adult screening is recommended.

Is hepatitis B treatment for life?

Often, though not always. Oral antivirals suppress the virus without removing its template from liver cells, so most people continue them for many years, and those with cirrhosis usually indefinitely, according to Mayo Clinic. Some people without cirrhosis can stop after sustained suppression under close supervision, and interferon is given as a finite course. The timeline is set by your prescribing team and revisited as results evolve.

What are the chronic hepatitis B treatment criteria specialists use?

Guidelines generally recommend treatment for anyone with cirrhosis, for people with raised ALT plus a meaningful viral load, particularly with fibrosis, and for those with HIV or hepatitis D coinfection, a family history of liver cancer, planned immunosuppression, or high viral load in late pregnancy. Exact thresholds differ between WHO and national guidelines and have broadened over time. Your specialist applies the guideline relevant to your setting.

Can I stop hepatitis B medicine once my viral load is undetectable?

Not on your own. An undetectable viral load means the medicine is working, not that the infection has cleared. Stopping without supervision can cause the virus to rebound and trigger a flare of inflammation, which is occasionally severe. Some people without cirrhosis may be candidates for a planned, monitored stop after prolonged suppression, but that decision, and the follow-up schedule around it, belongs to your prescribing team.

Does a normal ALT mean my liver is not being damaged?

It is reassuring but not conclusive. ALT can be normal in the immune-tolerant phase despite very high viral load, and in HBeAg-negative disease it often fluctuates, appearing normal at one visit and raised at the next. Specialists therefore repeat ALT and viral load over several months and add a stiffness scan or ultrasound to look for scarring directly before concluding that no treatment is needed.

Can I pass hepatitis B to my family if I am not on treatment?

You can, through blood, semen or vaginal fluid, though not through food, hugging, coughing or sharing dishes, according to the CDC. Household members and sexual partners should be tested and vaccinated if they are not immune. Avoid sharing razors, toothbrushes or nail tools, cover cuts, and use condoms until a partner is confirmed immune. Treatment lowers infectivity but does not replace these measures.

What happens if I have hepatitis B and become pregnant?

Tell your care team early. The CDC recommends hepatitis B testing in every pregnancy, and if your viral load is high in the third trimester, an antiviral may be offered to lower the baby’s exposure at birth. Regardless, your newborn should receive the first vaccine dose and hepatitis B immune globulin within 12 hours of birth, then complete the vaccine series. With these steps, transmission is uncommon and breastfeeding is considered safe.

References

• World Health Organization: Hepatitis B fact sheet
• CDC: About Hepatitis B
• NHS: Hepatitis B
• MedlinePlus: Hepatitis B

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.